Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables (2023 - 2025)

Historic Receivables for BioLineRx (BLRX) over the last 3 years, with Q2 2025 value amounting to $281000.0.

  • BioLineRx's Receivables fell 9267.28% to $281000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $281000.0, marking a year-over-year decrease of 9267.28%. This contributed to the annual value of $4.0 million for FY2024, which is 23282.83% up from last year.
  • Latest data reveals that BioLineRx reported Receivables of $281000.0 as of Q2 2025, which was down 9267.28% from $1.9 million recorded in Q1 2025.
  • BioLineRx's 5-year Receivables high stood at $4.0 million for Q3 2024, and its period low was $281000.0 during Q2 2025.
  • Moreover, its 3-year median value for Receivables was $3.3 million (2024), whereas its average is $2.6 million.
  • As far as peak fluctuations go, BioLineRx's Receivables soared by 23282.83% in 2024, and later plummeted by 9267.28% in 2025.
  • Over the past 3 years, BioLineRx's Receivables (Quarter) stood at $1.2 million in 2023, then skyrocketed by 232.83% to $4.0 million in 2024, then tumbled by 92.89% to $281000.0 in 2025.
  • Its Receivables stands at $281000.0 for Q2 2025, versus $1.9 million for Q1 2025 and $4.0 million for Q4 2024.